|
| |
Start Date: 1/23/2012 End Date:1/23/2013
| Which of the following professional societies best represents you? |
|
|
|
|
Start Date: 1/9/2012 End Date:1/9/2013
| Do you follow Appropriateness Criteria when performing PCI? |
|
|
|
| Not familiar with Appropriateness Criteria |
|
|
Start Date: 12/19/2011 End Date:12/19/2012
| Which of these six trials published in 2011 will have the most impact on clinical practice? |
| Partner Trial Cohort A (NEJM) |
|
|
|
| Resolute all comers (2 years) (LANCET) |
|
|
|
| RIVAL (radial vs femoral access) (LANCET) |
|
|
| LEADERS (4 years) (LANCET) |
|
|
Start Date: 11/23/2011 End Date:11/23/2012
| For patients undergoing PCI with atrial fibrillation, what type of stent should be used? |
|
|
Start Date: 11/7/2011 End Date:11/7/2012
| What impact do cardiologists have as hospital employees on the number of interventions performed? |
|
|
|
Start Date: 10/24/2011 End Date:10/24/2012
| Why is the uptake of Effient (prasugrel) low? |
|
|
| Black box and labeling related |
|
|
| Most physicians are comfortable with Plavix (clopidogrel) |
|
|
Start Date: 10/11/2011 End Date:10/11/2012
| What does the future hold for bioabsorbable scaffolds? |
|
| Will replace at least 30% of metallic stents |
|
|
|
Start Date: 9/26/2011 End Date:9/26/2012
| What is the main obstacle preventing the adoption of OCT in your cath lab? |
|
| Lack of data to support its use |
|
|
|
Start Date: 9/6/2011 End Date:9/6/2012
| Do you believe the stroke rates in the TAVR arm of PARTNER will impact the use of the technology in patients who cannot undergo surgical AVR? |
|
|
Start Date: 8/22/2011 End Date:8/22/2012
| How does the "unnecessary stenting" press impact your practice? |
|
|
| More careful to stent lesions >50%Â only |
|
|
Start Date: 8/1/2011 End Date:8/1/2012
| Now that Ticagrelor is approved, when should it be used? |
| In the majority of patients with ACS |
|
|
| Only in high risk pts for stent thrombosis |
|
|
| In non-responders to clopidogrel |
|
|
| Need more information to decide |
|
|
Start Date: 7/18/2011 End Date:7/18/2012
| What is your major concerns in regards to TAVR versus SAVR? |
|
| Higher vascular complication rate |
|
|
|
|
|
Start Date: 7/1/2011 End Date:7/1/2012
| Where do you see the future of PFO closure? |
| Primarily for stroke prevention |
|
|
| Primarily for treatment of Migraine headaches |
|
|
| No future, will remain niche procedure |
|
|
Start Date: 6/20/2011 End Date:6/20/2012
| What is your reaction to the stop in manufacturing of the CYPHER stent by the end of 2011? |
| The stent will be missed - I like to use it |
|
|
| It is about time - I stopped using it long time ago |
|
|
|
Start Date: 6/6/2011 End Date:6/6/2012
| What is your prediction in regards to the PCI volume for the next 6 months? |
|
|
|
Start Date: 5/23/2011 End Date:5/23/2012
| Do you believe that DES with biodegradable polymer has an advantage on DES with durable polymer? |
|
|
|
Start Date: 5/9/2011 End Date:5/9/2012
| How do you see the role of OCT in interventional cardiology? |
| Replacing IVUS for most cases |
|
|
|
| Niche usage in selected cases |
|
|
Start Date: 4/18/2011 End Date:4/18/2012
| How to reduce the stroke rate in TAVR? |
| Use protection device during valve implantation |
|
|
| Prescribe Warfarin post procedure for 3 months |
|
|
| Consider alternatives to femoral access |
|
|
Start Date: 4/4/2011 End Date:4/4/2012
| How will the results of the RIVAL trial impact the use of radial access? |
|
|
| Increase only in patients with AMI |
|
|
|
Start Date: 3/28/2011 End Date:3/28/2012
| If Partner Cohort A (TAVI vs surgical AVR for high risk patients with AS) meets the primary endpoint for non-inferiority how would you treat this patient population? |
|
|
| Depends on secondary endpoints |
|
|
| Decide based on team approach |
|
|
Start Date: 3/7/2011 End Date:5/7/2011
| What will be the mode of revascularization for unprotected of LM in the next year? |
|
|
|
Start Date: 2/14/2011 End Date:4/14/2011
| What will increase the use of radial access? |
| Training and education program |
|
|
| Randomized clinical trials: radial versus femoral |
|
|
| Pressure from hospital administrators |
|
|
Start Date: 1/24/2011 End Date:3/24/2011
| What are the main obstacles for carotid stenting? |
|
|
|
Start Date: 1/3/2011 End Date:1/3/2012
| Does the type of medical insurance government versus private influence outcome? |
| Government insurance is better |
|
|
| Private insurance is better |
|
|
| Outcome not related to type of insurance |
|
|
Start Date: 12/13/2010 End Date:12/31/2010
| Which of the studies presented or published at 2010 will have the most impact on the cardiology field? |
| PARTNER (TAVI vs medical therapy) |
|
|
| SIMPLICITY HTN 2 TRIAL (renal artery sympatetic denervation) |
|
|
| DEFINE (CETP inhibition with Anacetrapib) |
|
|
|
|
Start Date: 11/29/2010 End Date:12/29/2010
| What is your prediction for the use of IVUS and FFR in the next 6 months? |
|
|
|
|
Start Date: 11/16/2010 End Date:12/16/2010
| How will the results from the GRAVITAS trial impact measuring platelet responsiveness for patients undergoing PCI? |
|
|
|
Start Date: 11/8/2010 End Date:12/8/2010
| What is most important for an interventional cardiology meeting? |
|
|
| Sessions on complications |
|
|
|
Start Date: 10/18/2010 End Date:11/18/2010
| Based on the Horizon AMI Trial should DES approved for primary PCI? |
|
|
Start Date: 10/4/2010 End Date:11/4/2010
| Following the results of the PARTNER trial do you believe that it is ethical to randomize patients with aortic stenosis to balloon valvuloplasty or medical therapy alone? |
|
|
Start Date: 9/7/2010 End Date:10/7/2010
| How the results of the Current OASIS 7 Trial impact your practice? |
| More use of Clopidogrel 75 mg BID for 7 days |
|
|
|
|
Start Date: 8/23/2010 End Date:9/23/2010
| What is the preferred approach for percutaneous mitral valve repair? |
|
|
|
|
Start Date: 8/9/2010 End Date:9/1/2010
| Do you believe that the FDA regulatory requirements for approval of new devices for interventional cardiology are: |
|
| Too strict and delayes introduction of devices to the US market |
|
|
| Too easy and impose risks for patients |
|
|
Start Date: 7/26/2010 End Date:8/26/2010
| How many cardiology journals do you read each month? |
|
|
|
|
|
Start Date: 7/12/2010 End Date:7/26/2010
| Are you currently using the Syntax score to determine revascularization strategy? |
|
|
Start Date: 6/28/2010 End Date:8/15/2010
| Which test is currently used in your institution for responsiveness of antiplatelet therapy? |
|
|
|
|
Start Date: 6/14/2010 End Date:7/14/2010
| What will be the use of fully biodegradable stents once they approved for marketing? |
|
|
| No role in coronary arteries |
|
|
| Only for patients who cannot take Plavix |
|
|
Start Date: 5/26/2010 End Date:6/26/2010
| Do you believe that OCT will replace IVUS? |
|
|
Start Date: 5/10/2010 End Date:6/20/2010
| What is your prediction of the results of the Resolute All Comers study compared with Resolute versus Xience V, which will be presented at EuroPCR 2010? |
|
|
| No difference between Resolute and XIENCE V |
|
|
Start Date: 5/3/2010 End Date:5/30/2010
| Do you believe that there is a specific DES that is associated with better results in diabetic patients? |
|
|
Start Date: 4/19/2010 End Date:5/19/2010
| Do you believe that there are advantages for DES with bioabsorbable polymer over a DES with biocompatible durable polymer? |
|
|
Start Date: 4/5/2010 End Date:4/30/2010
| How will the health care bill impact your practice? |
|
| Significantly less reimbursement |
|
|
|
|
Start Date: 3/15/2010 End Date:4/15/2010
| Are the results from the EVEREST II Trial sufficient to approve the MITRALCLIP for patients with mitral regurgitation for commercial marketing in the US? |
| Yes, for the majority of patients with MR |
|
|
| No, need more data and long term follow-up to support approval |
|
|
| Yes, for selected patients with MR |
|
|
Start Date: 3/1/2010 End Date:3/15/2010
| How will the results of the CREST study impact the use of carotid stenting? |
| Increase the use of carotid stenting |
|
|
| Increase the use of carotid endarterectomy |
|
|
|
Start Date: 2/15/2010 End Date:3/15/2010
| Among the following societies, which one represent best the interventional cardiology community? |
|
|
|
|
Start Date: 2/1/2010 End Date:2/26/2010
| What is the main reason for not using Prasugrel for patients with ACS? |
|
| Don't have it in the Cath lab |
|
|
|
| Patients pre loaded with Clopidogrel |
|
|
Start Date: 1/25/2010 End Date:2/25/2010
| When you need to perform PCI to a second vessel what is your practice in relates to timing? |
| The same procedure if there are no renal impairment |
|
|
|
| In 4-6 weeks from the PCI to the primary vessel |
|
|
Start Date: 1/11/2010 End Date:2/14/2010
| What should be the primary endpoint for CABG versus PCI study for unprotected LM? |
|
|
|
Start Date: 12/21/2009 End Date:1/21/2010
| Which of the studies published or presented in 2009 will make most impact in 2010? |
|
|
|
|
|
|
|
Start Date: 12/7/2009 End Date:12/30/2009
| Which PFO should be closed? |
|
|
| Only post stroke and for migraine |
|
|
Start Date: 11/23/2009 End Date:12/23/2009
| How did the FDA warning in regards to an interaction between clopidogrel and the PPI will impact your practice? |
|
| Less use of PPI with clopidogrel |
|
|
| Less use of clopidogrel with PPI |
|
|
|
Start Date: 11/16/2009 End Date:11/24/2009
| Do you support performing elective PCI in hospitals without surgical backup? |
|
|
Start Date: 11/2/2009 End Date:11/20/2009
| Do you believe that there is sufficient evidence to change the guidelines in regards to PCI of unprotected LM? |
|
|
Start Date: 10/19/2009 End Date:11/20/2009
| How will the latest data from Current Oasis 7 change antiplatelet practice for patients with ACS? |
|
| More use of 600 mg versus (300 mg) as a loading dose |
|
|
| More use of 600 mg and 150 mg for the first week after PCI |
|
|
|
Start Date: 10/5/2009 End Date:10/29/2009
| How will the recent data on FFR (FAME)and IVUS (PROSPECT) will change their use in the cath lab? |
|
|
|
|
Start Date: 9/23/2009 End Date:10/29/2009
| Do you support the public option for healthcare reform? |
|
|
Start Date: 9/14/2009 End Date:9/29/2009
| What is your prediction to the results of SPIRIT IV: Xience V versus TAXUS Express? |
| XIENCE V superior for MACE |
|
|
| XIENCE V superior to TAXUS for TVF but non-inferior for TLR |
|
|
| XIENCE V non-inferior to TAXUS for MACE |
|
|
Start Date: 8/31/2009 End Date:9/14/2009
| What is the usage of FFR in your lab? |
|
|
|
|
Start Date: 8/24/2009 End Date:9/8/2009
| What is your prediction to the results of OASIS 7 study (higher loading dose (600 mg) and maintenance dose (150 mg daily) of Clopidogrel)? |
| Improved efficacy; no difference in bleeding |
|
|
| Improved efficacy but more bleeding |
|
|
| No difference in efficacy; no difference in bleeding |
|
|
| No difference in efficacy; but more bleeding |
|
|
Start Date: 8/10/2009 End Date:8/26/2009
| For patients with cardiogenic shock which device is more effective for hemodynamic support? |
|
|
|
| No major differences among the available devices |
|
|
Start Date: 7/27/2009 End Date:8/12/2009
| Will the use of DES increase with the approval of Prasugrel (Effient)? |
|
|
Start Date: 7/13/2009 End Date:7/29/2009
| How often will you use Prasugrel (Effient) for patients with acute MI? |
|
|
|
|
Start Date: 7/6/2009 End Date:7/13/2009
| Should the guidelines for PCI for unprotected LM be changed from class III? |
|
|
| No, more studies are needed |
|
|
Start Date: 6/22/2009 End Date:7/23/2009
| Do you support the new health care plan? |
|
|
Start Date: 6/15/2009 End Date:6/24/2009
| What will be the impact of the BARI 2D study results on the revascularization volume in diabetic patients? |
|
|
|
|
Start Date: 6/8/2009 End Date:6/20/2009
| Do you believe that proton pump inhibitors impacts platelet responsiveness? |
|
| Yes, but should not change the practice |
|
|
| Yes, but should not be prescribed to patients with DES on Plavix |
|
|
Start Date: 5/26/2009 End Date:6/26/2009
| Will the SYNTAX score be adopted by the interventional cardiology community? |
|
|
| I don't know what the SYNTAX score is. |
|
|
Start Date: 5/18/2009 End Date:5/27/2009
| Do you believe that DES with bioabsorbable polymers are safer when compared to DES with durable polymers? |
|
|
Start Date: 5/11/2009 End Date:5/20/2009
| What is the main reason not to use the radial approach? |
| Lack of knowledge/ training |
|
|
|
| I feel more comfortable with femoral access |
|
|
Start Date: 5/4/2009 End Date:5/13/2009
| What is the most important feature that influences DES selection? |
|
|
|
Start Date: 4/27/2009 End Date:5/5/2009
| The FDA advisory panel voted 7 to 5 to recommend the approval of the Watchman LAA closure device. Do you agree? |
|
|
Start Date: 4/20/2009 End Date:4/29/2009
| Which pattern of days do you prefer for interventional cardiology meetings? |
| Sunday, Monday and Tuesday |
|
|
| Monday, Tuesday and Wednesday |
|
|
| Wednesday, Thursday and Friday |
|
|
Start Date: 4/13/2009 End Date:4/22/2009
| Should patients be loaded with high dose Statin prior to PCI (ARMYDA-RECAPTURE)? |
|
| Only in elective patients |
|
|
| Need larger data to support this strategy |
|
|
Start Date: 4/6/2009 End Date:4/14/2009
| How frequently should radial access for PCI be used? |
|
|
|
Start Date: 3/30/2009 End Date:4/8/2009
| Do you believe that the FDA will approve marketing the Watchman device for atrial appendage closure based on the PROTECT AF data? |
|
|
Start Date: 3/23/2009 End Date:3/31/2009
| Should all non-responsive patients post CPR undergo cooling protocol? |
|
|
| Not familiar with the data |
|
|
Start Date: 3/16/2009 End Date:3/25/2009
| Should live cases in interventional courses be regulated by FDA and CME? |
|
|
Start Date: 3/9/2009 End Date:3/17/2009
| For patients undergoing PCI with DES, should the Clopidogrel dose be routinely tailored based on responsiveness? |
|
|
| Only in high risk patients |
|
|
Start Date: 3/2/2009 End Date:3/11/2009
| Will you use the Syntax score to determine who should undergo PCI or CABG? |
|
|
| I am not familiar with the Syntax score |
|
|
Start Date: 2/23/2009 End Date:3/3/2009
| Do you believe that the second generation drug-eluting stents are associated with less stent thrombosis when compared with the first generation Cypher and Taxus? |
|
|
Start Date: 2/16/2009 End Date:2/24/2009
| Would you continue to come to the major cardiology and interventional cardiology meetings if CME was not provided? |
|
|
Start Date: 2/9/2009 End Date:2/19/2009
| Will Prasugrel replace Clopidogrel once approved by the FDA? |
| Yes, in the majority of the patients |
|
|
| No, it will only be used for high risk patients with stent thrombosis |
|
|
| Yes, in the hospital, but patients will be prescribed Plavix upon discharge |
|
|
Start Date: 2/2/2009 End Date:2/9/2009
| Do you agree with the proposed legislation that drug and medical device manufacturers would need to publicly disclose all physician payments and gifts exceeding $100? |
|
|
Start Date: 1/26/2009 End Date:2/2/2009
| How will the results of the FAME study impact your practice in the cath lab? |
| I will increase the use of FFR |
|
|
| I will avoid angioplasty in intermediate lesions |
|
|
| The results will not impact my practice |
|
|
Start Date: 1/19/2009 End Date:1/26/2009
| What are your thoughts regarding the PCI guidelines? |
| I am familiar and adhere to the guidelines |
|
|
| I am familiar but do not adhere to the guidelines |
|
|
| There are too many guidelines |
|
|
| I am not familiar with the guidelines |
|
|
Start Date: 1/12/2009 End Date:1/19/2009
| What is the main reason for premature Plavix cessation? |
|
|
|
| Patients on too many pills |
|
|
Start Date: 1/5/2009 End Date:1/12/2009
| Is there a shortage of interventional cardiologists in your area? |
|
|
Start Date: 12/22/2008 End Date:1/6/2009
| Which of the following studies presented in 2008 will make most impact on clinical practice in 2009? |
|
|
|
|
|
Start Date: 12/15/2008 End Date:12/22/2008
| Will OCT have a role in clinical practice? |
|
|
|
Start Date: 12/8/2008 End Date:12/15/2008
| When do you use vascular closure devices? |
| All diagnostic and PCI cases |
|
|
|
| In PCI but not frequently |
|
|
Start Date: 12/1/2008 End Date:12/8/2008
| Do live case demonstrations jeopardize patient safety? |
|
|
Start Date: 11/24/2008 End Date:12/1/2008
| How does the economic crisis impact the cath lab in your hospital? |
| More patients with normal coronaries |
|
|
|
| Pressure from the administration on cost saving |
|
|
|
Start Date: 11/17/2008 End Date:11/24/2008
| How will the JUPITER study results impact your practice? |
| Order more hsCRP levels on low risk patients |
|
|
|
| Increase the use of statins not limited to Crestor |
|
|
| The study results will not impact my practice |
|
|
Start Date: 11/10/2008 End Date:11/17/2008
| Is there an application for the drug coated balloon? |
| Coronary use (ISR, bifurcation, de-novo) |
|
|
| Peripheral use (SFA, CLI) |
|
|
| Both coronary and peripheral |
|
|
|
Start Date: 11/3/2008 End Date:11/10/2008
| Should the Clopidogrel dose be adjusted based on testing for responsiveness? |
|
|
| Only for high risk patients for stent thrombosis |
|
|
Start Date: 10/27/2008 End Date:11/3/2008
| How often should IIB/IIIA inhibitors be used for primary PCI of patients with AMI? |
|
|
|
| Only when a clot is visible |
|
|
Start Date: 10/20/2008 End Date:10/27/2008
| How will the results of the Horizons AMI study impact the use of DES for AMI? |
| The results will increase the use of DES for AMI |
|
|
| The results will decrease the use of DES for AMI |
|
|
| The results will not change anything |
|
|
Start Date: 10/13/2008 End Date:10/20/2008
| Whose health care plan do you favor? |
|
|
|
Start Date: 10/6/2008 End Date:10/13/2008
| What is your prediction as to the results of the HORIZION-AMI (Taxus (DES) vs. Express (BMS) in patients with STEMI) trial? |
| Taxus is superior to Express |
|
|
| Taxus is non-inferior to Express |
|
|
| TAXUS reduced TLR but was less safe than Express |
|
|
Start Date: 9/29/2008 End Date:10/6/2008
| In your practice, for what percentage of patients it is realistic to achieve door to balloon time < 90 minutes? |
|
|
|
Start Date: 9/22/2008 End Date:9/29/2008
| Should the Advisory panel to the FDA recommend approval of Prasugrel for marketing? |
|
|
Start Date: 9/15/2008 End Date:9/22/2008
| How will the results of the SYNTAX study impact your practice on patients with multivessel disease and unprotected LM? |
|
|
|
Start Date: 9/8/2008 End Date:9/14/2008
| Do you believe that biodegradable polymers have an advantage in a DES? |
|
|
Start Date: 9/1/2008 End Date:9/7/2008
| Which of the following DES is the most effective for diabetic patients? |
|
|
|
|
| No difference among these stents |
|
|
Start Date: 8/25/2008 End Date:8/31/2008
| Will the SYNTAX study meets its primary clinical endpoint? |
|
|
|
Start Date: 8/18/2008 End Date:8/25/2008
| What impact will the quality of life data from the COURAGE trial have on PCI volume? |
| The data will increase PCI volume |
|
|
| The data will decrease PCI volume |
|
|
| The data will not influence PCI volume |
|
|
Start Date: 8/11/2008 End Date:8/20/2008
| What is the primary stent that XIENCE V / PROMOUS replaced in your lab? |
|
|
|
|
Start Date: 8/4/2008 End Date:8/10/2008
| What could be the main role of drug eluting balloons in PCI? |
|
| Treatment of in-stent restenosis |
|
|
| Denovo lesions with and without BMS |
|
|
|
Start Date: 7/28/2008 End Date:8/3/2008
| What is the best approach for patients with diffuse DES in-stent restenosis? |
|
|
|
|
Start Date: 7/21/2008 End Date:7/27/2008
| How is your PCI volume compared to last year? |
|
|
|
Start Date: 7/14/2008 End Date:7/20/2008
| What is your preferred lipid lowering agent in 2008? |
|
|
|
|
Start Date: 7/7/2008 End Date:7/13/2008
| With the approval of Xience, which of the four available stents will be your workhorse stent? |
|
|
|
|
Start Date: 6/30/2008 End Date:7/6/2008
| With the approval of Endeavor and Xience V/Promus what will determine your DES selection? |
|
|
|
|
Start Date: 6/23/2008 End Date:6/29/2008
| Which is your preferred hemodynamic support device for high risk PCI? |
|
|
|
Start Date: 6/16/2008 End Date:6/22/2008
| Which of the following societies best represents the field of interventional cardiology? |
|
|
|
|
Start Date: 6/9/2008 End Date:6/15/2008
| How many cardiology journals do you read per month? |
|
|
| | |